Clinical trials: Mood
Major Depressive Disorder
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
- Trial name
- NCT00905424
- Testing
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Where
- 15 sites in United States
- Volunteers
- 246 people
- Sponsor
- Shire
Depressive Disorder
An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression
The purpose of this study is to evaluate the effectiveness of two adaptive treatment strategies (ATSs) for adolescent depression.
- Trial name
- NCT03222570
- Testing
- Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Minnesota
Major Depression
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
Participating subjects are those who are referred for electroconvulsive therapy (ECT) for severe depression who have agreed to the protocol. The control group receives ECT as usual.
- Trial name
- NCT00616759
- Testing
- electroconvulsive therapy, electroconvulsive therapy plus propofol, propofol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Loma Linda University
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Opioid-use Disorder, Anxiety Disorders
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
The majority of opioid users meet criteria for anxiety and depressive disorders, but most substance use disorder treatment programs do not offer treatment for co-occurring mental health problems.
- Conditions
- Opioid-use Disorder, Anxiety Disorders, Depressive Disorder
- Trial name
- NCT05047627
- Testing
- Smartphone-Based Digital Intervention
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Trustees of Dartmouth College
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study
This protocol, "Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder (MDD): A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study," is an open-label pilot treatment…
- Trial name
- NCT01162382
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Premature Birth, Pregnancy Preterm
Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study
This is a randomized comparative effectiveness study of two forms of enhanced prenatal care among 674 Medi-Cal eligible pregnant individuals in Fresno, California.
- Conditions
- Premature Birth, Pregnancy Preterm, Prenatal Stress, Depression, Anxiety
- Trial name
- EMBRACE (NCT04154423)
- Testing
- Glow! Group Prenatal Care, Individual Prenatal Care with CPSP
- Where
- 2 sites in United States
- Volunteers
- 678 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Bipolar Depression
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.
- Trial name
- NCT01479829
- Testing
- Escitalopram, Celecoxib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With MDD
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03560518
- Testing
- Rapastinel
- Where
- 40 sites in United States
- Volunteers
- 439 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Parkinson's Disease
Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study
To investigate the efficacy of Mindfulness-based Stress Reduction (MBSR) to improve quality of life, cognition, and mood, as well as to determine the longevity of the treatment response in individuals with Parkinson's disease…
- Trial name
- MBSR (NCT03998462)
- Testing
- Mindfulness Based Stress Reduction, Psychoeducational Supportive Care
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- VA Office of Research and Development
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
PMDD, Stress
Stress & Premenstrual Symptoms Study
This study that aims to evaluate the psychophysiology of premenstrual mood disorders (PMDs) at baseline and after treatment with sertraline. Participants will include women with PMDs and healthy female controls.
- Conditions
- PMDD, Stress, Mood
- Trial name
- NCT02777372
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
- Trial name
- NCT01670279
- Testing
- Brexpiprazole
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Stress and the Sympathetic Nervous System in Adults With Depression
To test our hypotheses, we will enroll healthy adults having no history of mood disorders and adults with major depressive disorder (MDD) having a broad range of depressive symptom severity.
- Trial name
- NCT04838262
- Testing
- Acute Stressors
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.
- Trial name
- NCT00532480
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.